Table of Contents Author Guidelines Submit a Manuscript

Low-risk Thyroid Cancer Treatment

Call for Papers

Differentiated thyroid cancer (DTC) is a generally indolent disease, although cases with certain clinicopathological features are progressive and life-threatening. Currently, the treatment strategies of DTC are quite uniform worldwide: total thyroidectomy, radioactive iodine (RAI) ablation, and thyroid-stimulating hormone (TSH) suppression. Such a stereotyped treatment might be easy for physicians, but it might be an overtreatment for many DTC patients without high-risk features and predicting an excellent prognosis. Recently, in some institutions, trials of observation and limited surgery for low-risk patients have been performed, and the dose of RAI for ablation came to be reduced for patients who were classified as low-risk based on clinicopathologic features. Unfortunately, comparable studies are very hard to perform, but therapeutic experience for low-risk DTC patients is now being accumulated in many institutions.

We invite papers demonstrating an experience of treatment for low-risk DTC patients in the fields of surgery, radiology, pathology, and endocrinology. Potential topics include, but are not limited to:

  • Limited surgery for low-risk DTC: extent of thyroidectomy and prophylactic lymph node dissection
  • Indication of completion total thyroidectomy for patients who underwent limited surgery under the diagnosis of adenomatous nodule or follicular tumor but were pathological diagnosed as follicular (or papillary) carcinoma
  • Indication of postoperative RAI ablation for low-risk DTC patients: its necessity or unnecessity and dose of RAI
  • Indication of TSH suppression therapy: its necessity or unnecessity and appropriate TSH levels
  • Relationship between pathological examination and prognosis of low-risk DTC patients
  • How to follow low-risk DTC patients after surgery (and RAI ablation): constant examination by specialist is necessary?

Before submission authors should carefully read over the journal's Author Guidelines, which are located at Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at according to the following timetable:

Manuscript DueFriday, 25 January 2013
First Round of ReviewsFriday, 19 April 2013
Publication DateFriday, 14 June 2013

Lead Guest Editor

  • Yasuhiro Ito, Department of Surgery, Kuma Hospital, Kobe, Japan

Guest Editors

  • R. Michael Tuttle, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY, USA
  • Hang-Seok Chang, Gangnam Severance Hospital, Yonsei University, Seoul, Republic of Korea